NCT00001823 Evaluation for NCI Surgery Branch Clinical Research Protocols
| NCT ID | NCT00001823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Synovial Cell Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 1999-07-11 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 1999-07-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol. Design Patients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol.
Eligibility Criteria
* INCLUSION CRITERIA: Age \>= 18 years. Patient suspected of having, or with biopsy proven, malignant disease. Patient is able to understand and willing to sign a written informed consent document. Patient is being evaluated for treatment on an NCI-SB protocols. EXCLUSION CRITERIA: Women of child-bearing potential who are pregnant or plan to become pregnant because of the potentially dangerous effects of some of the screening procedures (e.g., nuclear medicine or other imaging scans) on the fetus.
Contact & Investigator
Steven A Rosenberg, M.D.
PRINCIPAL INVESTIGATOR
National Cancer Institute (NCI)
Frequently Asked Questions
Who can join the NCT00001823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Synovial Cell Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00001823 currently recruiting?
Yes, NCT00001823 is actively recruiting participants. Contact the research team at irc@nih.gov for enrollment information.
Where is the NCT00001823 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00001823 clinical trial?
NCT00001823 is sponsored by National Cancer Institute (NCI). The principal investigator is Steven A Rosenberg, M.D. at National Cancer Institute (NCI). The trial plans to enroll 7,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.